Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced updated data from MM-003, the Company’s phase III international study evaluating POMALYST® (pomalidomide) plus low-dose dexamethasone versus high-dose dexamethasone in relapsed or refractory multiple myeloma patients who had received at least two prior treatment regimens, failed both lenalidomide and bortezomib and had demonstrated disease progression on their last therapy, were presented in a June 3 oral session at the American Society of Clinical Oncology 2013 Annual Meeting (ASCO) in Chicago, Ill.
Help employers find you! Check out all the jobs and post your resume.
